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1. Introduction 
In several biological in vitro systems such as the rat 
diaphragm [ 1 ], rat epididymal dipose tissue [2] or 
isolated fat ceils [3,4] human serum exerts insulin- 
like effects which cannot be 'neutralized' by the 
addition of insulin antibodies. This activity has been 
designated asnonsuppressible insulin-like activity 
(NSILA) [2]. Two fractions of NSILA had been 
obtained earlier by acid/ethanol extraction of acetone 
powder prepared from human serum: one of small 
molecular weight, soluble in acid/ethanol, which was 
called NSILA-S [5] ; and one of large molecular 
weight, precipitated by acid/ethanol, and termed 
NSILA-P in [5]. NSILA-S has been further purified. 
It has been shown to contain 2 insulin-like poly- 
peptides (termed insulin-like growth factors, IGF I 
and II) whose chemical [6-8] and biological properties 
[9] have been defined. The 2 polypeptides occur in 
human serum in tight association with a specific 
carrier protein [10] from which they dissociate under 
acidic conditions [ 11,12]. Doubts have, however, been 
raised about he existence of NSILA-P. Chromatog- 
raphy of human serum on Sephadex G-75 in 1 M 
acetic acid, did not reveal measurable amounts of 
large mol. wt NSILA. They recovered all the insulin- 
like activity in a small mol. wt fraction 0nol. wt 
<10 000) [ 11 ]. Recently, Poffenbarger, using 
Dowex.50 ion exchange chromatography as the 
first purification step, isolated alarge mol. wt insulin- 
like protein (NSILP) which, like NSILA-P, could no 
longer be dissociated into small mol. wt NSILA by 
acid treatment [ 13]. 
In this work we tried to reassess the problem with 
the methods applied in our earlier studies [11,12]. 
Avoiding lyophilization of the large mol. wt serum 
fractions in acetic acid we were able to demonstrate 
that, besides mall mol. wt NSILA bound to carrier 
protein, human serum contains considerable amounts 
of large mol. wt NSILA which cannot be converted to 
the small mol. wt form under acidic conditions and 
which does not cross-react with l~SI-labelled NSILA-S 
on the NSILA-carrier protein. 
2. Materials and methods 
2.1. Serum chromatography 
A. Four 20 ml samples of a normal human serum pool 
were chromatographed on a Sephadex G-200 
column (bed vol. 1000 ml, diam. 4 cm) in 0.1 M 
phosphate buffer, pH 7.4. Fractions were pooled 
between 30% and 40% and then every 5% of the 
bed volume, concentrated byultrafdtration to
4-6 ml and dialyzed against Krebs-Ringer bicar- 
bonate buffer. In each of these serum fractions 
total NSILA was determined in the presence of 
2 p.l guinea pig anti-insulin serum (insulin-neutraliz- 
ing capacity 2mU) in the fat pad assay [2] and in 
a fat cell (FC) assay which measures the stimula- 
tion of lipid synthesis from [U-14C] glucose as in 
[ 14-16]. Different dilutions of crystalline porcine 
insulin served as reference standards. 
B. Samples, 1.5 ml, of each of the neutral concen- 
trated serum fractions obtained in A, were chro- 
matographed onSephadex G-50 (bed vol. 100 ml, 
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diam. 1 cm) in 1 M acetic acid. This procedure has 
been shown to result in dissociation of small mol. 
wt NSILA from its carrie r protein [11,12,17-19]. 
Fractions eluting between 30% and 50% bed vol. 
were pooled (30-50% pools), concentrated by
ultraf'fltration, dialyzed against Krebs-Ringer 
bicarbonate buffer, and NSILA was measured in
the fat pad and FC assays (see A). The fractions 
eluting between 50-55%, 55-60% and 60-85% 
bed vol. were pooled, lyophilized, dissolved in 
2 ml 0.1 M (NH4)2COa, and NSILA was determined 
by a competitive protein binding assay using 
12SI-labelled NSILA-S as a tracer and different 
dilutions of unlabelled NSILA-S (3.8 mU/mg) for 
standardization as detailed in [12]. Aliquots, 
0.7 ml, of the 3 pools were then recombined in
1 pool (50-85% pools), relyophilized and dis- 
solved in Krebs-Ringer bicarbonate buffer con- 
taining 0.2% human serum albumin (HSA). NSILA 
was then determined biologically in the fat pad and 
FC assays. 
of 30-50% pools (B)(after dialysis against 0.1 M 
phosphate buffer, pH 7.0) obtained after removal of 
small tool. wt NSILA by acidic chromatography of 
the neutral fractions. The method for the determina- 
tion of 12Sl.labelled NSILA-S binding activity has been 
detailed in [ 10,19]. Total binding (in the absence of 
added unlabelled NSILA-S) and nonspecific binding 
(in the presence of excess unlabelled NSILA-S: 
250 #U/ml) were measured in duplicate at different 
dilutions of the samples in order to find out the 
range where specific binding (difference between total 
and nonspecific binding) became linearly related to 
the dilution. Specific binding was then expressed as 
'relative specific 12s I-labelled NSILA-S binding activity' 
(cpm bound/fraction rpool). 
The iodination procedure for NSILA-S as well as 
the characteristics of the labelled preparation have 
been described [ 12,20]. 
3. Results and discussion 
2.2. Determination fNSILA, of 12SI-labelled NSILA-S 
binding activity and presentation fresults 
All NSILA determinations were done in duplicate 
and, when the NSILA concentration allowed it, at 
2 different dilutions. In A, the results were expressed 
as total gU NSILA (in terms of insulin equivalents in
the fat pad or the FC assay) per serum fraction. In 
B, NSILA was calculated a~/aU contained in the 
30-50% or 50-85% pools of the whole respective 
serum fraction from which they were obtained. Again, 
~aU measured in the fat pad and FC assays refer to 
insulin equivalents. The competitive protein binding 
assay can only be applied to the determination f 
small mol. wt NSILA in the absence of contaminating 
binding protein [12]. Therefore, only 50-85% pools 
could be assayed./~U determined in the protein 
binding assay refer to NSILA-S as the standard. There 
is a good correlation between the fat pad and the 
protein binding assay, although 2-fold higher than in 
the fat pad assay [12], (table 1). For unknown 
reasons, the results of the FC assay are also 2-fold 
higher than those of the fat pad assay and usually 
agree with those obtained in the protein binding assay. 
Specific 12SI-labelled NSILA-S binding was deter- 
mined in 2% bed vol. fractions after neutral Sephadex 
G-200 chromatography of serum (A) and in aliquots 
The results of this study are presented in fig.lA 
and 1B and in table 1. Unextracted normal whole 
serum contains ~200 ~uU/ml of NSILA as determined 
in the fat pad assay [11,21]. The serum pool used in 
this study contained 195/aU/ml. After passage over 
Sephadex G.200 at neutral pH the recovery was 276%, 
a still unexplained observation made also in [21 ]. The 
peak of NSILA eluted between 50% and 60% bed vol. 
(mol. wt 90 000-160 000) as in [21]. This was 
surprising, since we should have expected 2 NSILA 
peaks coinciding with the 2 major 12SI-labelled 
NSILA-S binding peaks at Kay 0.2 and 0.5 (47% and 
66% bed vol.). When the NSILA peak fractions 
between 50-55% and 55-60% bed vol. were chro- 
matographed onSephadex G-50 in 1 M acetic acid 
the total recovery of NSILA (30-50% plus 50-85% 
pools, fig. 1 B) was 77% (41% in the FC assay) (table 1). 
However, only 12% (563/aU; FC assay: 1560/aU = 15%) 
and 7% (286/aU; FC assay: 234 #U = 3%), respectively 
appear as small mol. wt NSILA in the 50-85% pools, 
whereas the rest (3042 #U and 2627/aU; FC assay: 
2824 #U and 2413/aU) elutes in the 30-50% pools 
(table 1). The amounts of NSILA measured in the 
protein binding assay in the 50-85% pools (1093 taU 
and 288/aU) agree with those determined in the FC 
assay (table 1). 
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Fig.lA. Total NSILA and relative a2SI-labelled NSILA-S binding activities in fractions of human serum after chromatography on 
Sephadex G-200 in 0.1 M phosphate buffer, pH 7.4. Normal serum, 20 ml, was chromatographed on Sephadex G-200 at neutral 
pH. Specific ~2Slqabclled NSILA-S binding activity (o -o) was measured in 2% bed vol. fractions. NSILA (hatched columns) 
was determined by the rat fat pad assay in 5% bed vol. fractions. AU determinations were carried out in duplicate and, for NSILA, 
at 2 different dilutions. 4different experiments were carried out with the same pool of normal human serum. Bars give the SEM 
of these 4 experiments. 
In contrast, when the binding peak fraction 
between 45% and 50% bed vol. (after neutral chro- 
matography on Sephadex G-200) is chromatographed 
in 1 M acetic acid, 60% (567/IU) of its NSILA is dis- 
sociated, apparently representing carrier-bound small 
mol. wt form, whereas only 29% (270/aLl) elute in 
the 30-50% pool (fig.lB and table 1). The results of 
the FC assay give a similar picture (1024 #U = 65% 
in the 50-85% pool, 268 #U = 23% in the 30-50% 
pool) and agree with those of the protein binding 
assay (1071/aU in the 50-85% pool). 
More NSILA binding sites should become available 
on the binding protein after dissociation of small mol. 
wt NSILA. This is indeed the case: the specific relative 
12SI-labelled NSILA-S binding activity of the binding 
fractions between 40% and 55% bed vol. increases 
~20-fold, that of the binding fractions between 55% 
and 75% bed vol., which contain less dissociable 
NSILA, only ~2-fold. Since the 2 binding peaks in A 
overlap with the NSILA peak and since rechromatog- 
raphy of the 30-50% pools of the NSILA peak in 
1 M acetic acid does not result in further measurable 
dissociation of small mol. wt NSILA, we assume that 
the small mol. wt NSILA dissociated from the NSILA 
peak fractions (50-60% bed vol. in A) also represents 
NSILA originally associated with binding protein. By 
the same token, large mol. wt NSILA recovered in the 
2 binding peaks probably belongs to the NSILA peak. 
Altogether, this means that most of the dissociable 
small mol. wt NSILA (70-80%) is carried by the 
binding protein fraction with Kay 0.2 and only 
20-30% by the one with Kay 0.5 (fig.1A). 
These f'mdings together with those in [ 13] strongly 
favour the earlier concept [5] according to which at 
least 2 forms of NSILA are present in human serum: 
1. Carrier-bound NSILA, which dissociates as small 
mol. wt NSILA under acidic conditions (10,19) 
2. Large mol. wt NSILA, which is not intercon- 
vertible to the small mol. wt form by acid treat- 
ment. 
However, whereas we detected ~16% of the total 
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Fig.lB. NSILA in 50-85% (small mol. wt NSILA) and in 30-50% pools (large mol. wt NSILA), and relative t2SI-labelled 
NSILA-S binding activities in 30-50% pools, obtained by chromatography on Sephadex G-50 in 1 M acetic acid of the serum 
fractions from experiment A. Ultraf'fltered 5% bed vol. fractions from A were passed over Sephadex G-50 in 1 M acetic add. 
Fractions were pooled between 30-50% and 50-85% bed vol. as in section 2. Specific ~sI-iabelled NSILA-S binding activity 
(hatched columns) and NSILA (rat fat pad assay; cross-hatched columns) were determined in the 30-50% pools after ultra- 
filtration on dialysis (see texO. Small mol. wt NSILA (open columns) was measured in the lyophilized 50-85% pools by the fat 
pad assay (see also table 1). The height of the columns gives the mean of 4 different experiments, each started from step IA. 
Bars give the SEM of these 4 experiments. Triangles indicate NSILA values below the limit of sensitivity of the assay. 
NSILA, recovered after fractionation of serum by 
neutral Sephadex chromatography, to be bound to 
carrier protein and to be dissociable as small reel. wt 
NSILA, it could not be detected in [13]. Recent 
investigations (Kaufmann, J. Z. and E. R. F., in prep- 
aration) indicate that this seems to be due to the 
different methodological pproach. The explanation 
why we did not find large mol. wt NSILA during 
recent years lies in the fact that all serum fractions 
obtained by acidic Sephadex chromatography were 
lyophilized in 1 M acetic acid. This causes a nearly 
total loss of  large mol. wt NSILA. Lyophilization 
at neutral pH, however, does not result in losses of 
its biological activity. 
We do not yet know whether the large mol. wt 
NSILA fraction described here is identical to NSILA-P 
[5] or to NSILP [13], or whether it is a precursor of  
NSILA-S. So far, we have not yet made an attempt o 
further characterize it physico-chemicaUy or to test 
it for other biological effects. Preliminary studies 
have shown that the partially purified large mol. wt 
NSILA fraction, devoid of  12SI-labelled NSILA-S 
binding activity, does not cross-react with 12Sl.labelled 
NSILA-S in the protein binding assay nor with 
12SI-labelled IGF I in an IGF I-radioimmunoassay 
(unpublished observation). 
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